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INTRODUCTION
In the process of treating patients for hematologic
malignancies, clinicians are often faced with a decision
between an autologous transplantation or an allogeneic
transplantation from a related or unrelated donor. The fac-
tors favoring an autologous transplantation include re l a-
tively low tre a t m e n t - related morbidity and mortality and
low cost compared with allogeneic transplantation. Consid-
erations, however, must also include the feasibility of
obtaining suitable autologous stem cells from the patient.
The major advantages of an allogeneic transplantation
include decreased relapse rate compared with autografts,
owing to the graft-versus-leukemia (GVL) effect [1,2].
U n f o rt u n a t e l y, few studies have directly compared the
results of autologous and allogeneic transplantations in
l a rge numbers of patients in specific disease categories. For
example, several studies have compared the outcomes of
intensive chemotherapy consolidation and allogeneic or
autologous transplantation in fir s t - remission acute myeloid
leukemia (AML), but the results have been inconsistent,
with allogeneic transplantations appearing to have a slight
edge in disease-free survival (DFS) but an unclear advan-
tage in overall survival [3-5]. Thus, without clear evidence
of the superiority of 1 transplant type over another, the
choice between an autologous or allogeneic transplantation
often revolves around patient age, comorbid conditions, or
patient and physician choice.
Whether patients who relapse after an autologous trans-
plantation can be saved with a subsequent allogeneic trans-
plantation is of interest for 2 reasons. First, there is the
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ABSTRACT
We evaluated the outcome of second allogeneic bone marrow transplantations (BMTs) in 59 patients aged 1-57 years
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(DFS) 2 years after the second BMT were 51%, 26%, and 23%, re s p e c t i v e l y. The 2-year DFS estimates for AML,
ALL, and lymphoma were 46%, 23%, and 0%. Univariate analysis demonstrated that superior DFS was associated with
age ≤17 years at the time of the second transplantation, remission before the second transplantation, total-body irr a d i-
ation–based preparative regimen for the second transplantation, and the diagnosis of AML. These data demonstrate
that an allogeneic transplantation after a failed autologous transplantation can result in disease-free survivors, espe-
cially in the young. The outcomes after a second transplantation for patients aged >17 years and for those with lym-
phoma were especially grim. These data suggest that pediatric patients may be appropriate candidates for a second
transplantation. In adults, however, the use of an allogeneic transplantation as salvage therapy after failure of the initial
autologous transplantation is generally unsuccessful. Alternative experimental strategies, such as low-dose nonmye-
loablative allogeneic minitransplantations, should be considere d .
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practical problem that many patients relapse after an autolo-
gous transplantation and have few other treatment options
[6,7]. Second, in the unusual circumstance where either allo-
geneic or autologous transplantation may be perf o rm e d ,
physicians and patients might consider using autologous
transplantation and re s e rving allogeneic transplantation for
salvage therapy if the autologous transplantation fails. To
examine these questions, we analyzed the results of 59 con-
secutive patients in whom a second allogeneic transplantation
was perf o rmed after an initial autologous transplant failed.
MATERIALS AND METHODS
F rom May 1986 through December 1997, 59 patients
with hematopoietic malignancies received a second allogeneic
m a rrow transplantation at the Fred Hutchinson Cancer
R e s e a rch Center (FHCRC) for re c u rrent AML (n = 24),
acute lymphocytic leukemia (ALL) (n = 13), Hodgkin’s dis-
ease or non-Hodgkin’s lymphoma (NHL) (n = 18), multiple
myeloma (n = 3), or chronic myelogenous leukemia (CML)
( n = 1). In the majority of patients, the first autologous trans-
plantation was perf o rmed at an institution other than
FHCRC. Results were analyzed as of January 14, 1999.
Second Transplantation Characteristics
As a general rule, patients who received chemotherapy-
only preparative regimens for their first transplantation
received a regimen containing total-body irradiation (TBI)
for their second transplantation. If patients had re c e i v e d
TBI or dose-l i miting radiation before their second trans-
plantation, they generally received a chemotherapy-only
regimen for their second transplantation. TBI of 12.0 to
15.75 Gy was delivered in fractionated or hyperf r a c t i o n-
ated doses [8-10]. In sum, 32 patients received a TBI-
containing regimen for their second transplantation, and 27
had a chemotherapy-only preparative regimen. Patients who
w e re transplanted from an HLA-mismatched donor also
received antithymocyte globulin (ATG) as part of their
preparative regimen [11]. 
HLA histocompatibility testing was perf o rmed at
FHCRC for all patients and donors. Mismatched re l a t e d
donors were matched for HLA-A, -B, and –DR/DRB1 on
one haplotype and could be mismatched for 1 HLA antigen
on the second haplotype. Unrelated donors were matched
for HLA-A, -B, and DR/DRB1 (both haplotypes). All allo-
geneic transplant recipients received unmanipulated bone
marrow cells. 
Engraftment was defined as the first of 3 consecutive
days in which neutrophils exceeded 500/µL. Patients were
not considered evaluable for engraftment if they died before
day 40 without a neutrophil count >500/µL.
Donor engraftment was determined by in situ DNA
hybridization with a Y body–specific probe in sex-mis-
matched transplants [12] or by polymerase chain re a c-
tion–mediated analysis of variable number of tandem
repeats [13].
Graft-versus-host disease (GVHD) prophylaxis with
m e t h o t rexate and cyclosporine has been described [14].
Patients who developed acute GVHD were treated with
high-dose prednisone or ATG [11]. Chronic GVHD was
t reated with prednisone with or without cyclosporine [15].
P rophylaxis for cytomegalovirus, fungal, and P n e u m o c y t i s
c a r i n i i infection was given as previously described [16,17].
The grading and treatment of re g i m e n - related toxicity,
veno-occlusive disease (VOD), acute GVHD, and chro n i c
GVHD have been described [1,18]. 
All protocols and consent were approved by the FHCRC
Institutional Review Board. The pro c e d u res, along with the
risks and benefits, were explained in detail to patients, par-
ents, and donors, all of whom gave informed consent. 
Statistical Anal y s i s
P robability of DFS (survival without relapse) was esti-
mated by the method of Kaplan and Meier [19], and the
p robabilities of relapse and nonrelapse mortality (NRM)
w e re estimated using cumulative incidence estimates [20].
For the endpoint of relapse, death without relapse was
regarded as a competing risk, whereas relapse was regarded
as a competing risk for NRM. Cox regression models were
fitted to examine the association of various clinical risk fac-
tors with the hazard of failure from death or relapse (21).
Factors examined included age at second transplantation
(analyzed as a continuous variable as well as ≤17 versus >17
years), time from first to second transplantation (as a contin-
uous variable as well as ≤1 versus >1 year), phase of disease
at second transplantation (relapse versus remission), type of
donor (matched related versus mismatched related versus
unrelated), preparative regimen for second transplantation
( T B I - c o ntaining versus chemotherapy only), and diagnosis
(AML versus ALL versus lymphoma versus other). These
same factors were examined for an association with the haz-
ard of relapse, and acute and chronic GVHD were further
considered as time-dependent covariates in regression mod-
els for relapse. The significance of the correlation between
risk factors was examined using chi-square test if each factor
was categorical and Wilcoxon rank sum test if 1 of the fac-
tors was continuous. Two-sided P values resulting from the
regression models were derived using the Wald test, and no
adjustments were made for multiple comparisons.
RESULTS
Patient Characteristics 
The diagnosis, age, donor type, and phase of disease for
the 59 second transplantation patients are shown in Table 1.
The median time between first and second transplantation
was 411 days (range, 54-2681). The median age for the 59
patients was 28 years (range, 1-57), and age varied signifi-
cantly between diagnostic groups (P < .001), with the
youngest group being AML cases (median 16 years). Over-
all, 14 patients received a second BMT from an HLA-
identical relative, 25 from a mismatched relative, and 20
f rom an unrelated donor (URD). Eighteen patients were
transplanted in remission, and 41 were transplanted in
relapse. Patients with lymphoma tended to be transplanted
with advanced disease—15 of 18 (83%) of the lymphoma
patients received their second BMT in relapse, compare d
with 26 of the 41 (63%) remaining patients (P = .13).
E n g r a f t m e n t
Twelve patients died of regimen-related toxicity before
day 40 and were not evaluable for engraftment. The
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re m a i ning 47 patients all engrafted, with a median time to
engraftment of 18 days (range, 9-32). 
N o n re l a pse Mor t a l i t y
A summary of NRM is shown in Table 2. The day-100
NRM was estimated to be 41%, and NRM at 2 years was
estimated to be 51%. The causes of NRM are shown in
Table 3. Patients who died in relapse after the second trans-
plantation were considered to have died of recurrent disease
i rrespective of the immediate cause of death. In addition,
patients who died with grade IV GVHD were considered to
have died of GVHD even in the presence of a concurre n t
l i f e - t h reatening infection. Of the 32 nonrelapse deaths,
GVHD was the most common cause, responsible for 7 early
deaths from acute GVHD and 4 late deaths from chro n i c
GVHD. Infections and VOD accounted for 6 deaths apiece.
Overall, 19 of the 32 nonrelapse deaths occurred on or
before day 50 post-BMT.
NRM was especially high in patients >17 years of age, as
well as in lymphoma patients (Table 2). In patients ≤17 years,
only 2 of 17 died of nonrelapse causes (12%), whereas 30 of
42 (71%) patients >17 years died of nonrelapse causes, and
the estimated 2-year NRMs were 6% and 70%, re s p e c t i v e l y.
In lymphoma patients, 14 of 18 suff e red NRM compare d
with 8 of 13 nonrelapse deaths in ALL patients and 8 of
24 n o n relapse deaths in AML patients (estimated 2-year
NRMs 78%, 54%, and 34%). Some of the high NRM eff e c t
in the lymphoma population is likely due to the signific a n t
impact of age on NRM: lymphoma patients were signific a n t l y
older than patients with AML (median age 37 versus 16 years). 
R e l ap s e
Relapse experience is summarized in Table 2. The
cumulative incidence estimate of relapse at 2 years after sec-
ond BMT among all patients was 26% (Figure 1). The esti-
mated relapse rates for AML, ALL, lymphoma, and other
diseases at 2 years were 25%, 23%, 22%, and 0%, respec-
tively. There was no statistically significant difference in the
h a z a rd of relapse across diff e rent donor types or phases of
disease at second transplantation. The relapse rates at 2
years for matched related, mismatched related, and unre-
lated transplants were estimated to be 14%, 28%, and 31%,
and the relapse estimates for patients transplanted in remis-
sion and relapse were 22% and 27%.
Relapse was also influenced by the presence of acute
GVHD. The hazard ratio (HR) of relapse for patients with
acute GVHD grades II to IV versus those with grades 0 to I
was 0.3 (95% confidence interval [CI] 0.1-0.9; P = .03). The
Table 1. Patient Characteristics at Second Transplantation
Age in Years HLA-Identical HLA-Mismatched Unrelated
Diagnosis (Range) Related Donor Related Donor Donor Remission Relapse Total
Acute lymphoblastic leukemia 22 (6-42) 1 8 4 5 8 13
Acute myelogenous leukemia 16 (1-48) 2 10 12 9 15 24
Lymphoma 37 (19-56) 11 5 2 3 15 18
Multiple myeloma 46 (41-57) 0 2 1 0 3 3
Chronic myelogenous leukemia 24 0 0 1 1 0 1
Total 28 (1-57) 14 25 20 18 41 59
Table 2. Outcomes After Second Transplantation*
n Nonrelapse Mortality Relapse Disease-Free Survival
Diagnosis
Acute myelogenous leukemia 24 08 (30) 06 (25) 10 (46)
Acute lymphoblastic leukemia 13 08 (54) 03 (23) 02 (23)
Lymphoma 18 14 (78) 04 (22) 00 (0)
Multiple myeloma 03 02 01 00
Chronic myelogenous leukemia 01 00 01 00
Phase at transplantation
Remission 18 06 (28) 04 (22) 08 (50)
Relapse 41 26 (61) 11 (27) 04 (12)
Age at transplantation (years)
≤17 17 02 (6) 06 (35) 09 (59)
>17 42 30 (70) 09 (22) 03 (9)
Donor type
Related matched 14 10 (71) 02 (14) 02 (14)
Related mismatched 25 12 (41) 07 (28) 06 (32)
Unrelated 20 10 (50) 05 (31) 04 (19)
*Data are n (%). Outcome estimates in parentheses were calculated using cumulative incidence estimate for nonrelapse mortality and relapse and the Kaplan-
Meier estimate for disease-free survival. Estimates in parentheses were taken 2 years after the second transplantation. Estimates are not given for CML or multi-
ple myeloma patients because of the small number of cases.
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p resence of acute GVHD was still significantly associated
with a lower hazard ratio of relapse after adjusting by the
phase of disease (HR = 0.3; 95% CI 0.1-1.0; P = .05), age
≤17 versus >17 years (HR = 0.3; 95% CI 0.1-0.9; P = .04), or
AML versus other diagnoses (HR = 0.3; 95% CI 0.1-1.0;
P = .05). After adjusting for use of TBI, the hazard of
relapse was still lower among patients with acute GVHD,
although the diff e rence did not remain statistically signifi-
cant (HR = 0.5; 95% CI 0.1-0.7; P = .25). The presence of
clinically extensive chronic GVHD was also associated with
a decreased hazard of relapse but was not statistically signifi-
cant (HR = 0.4; 95% CI 0.1-1.4; P = .15). The hazard
remained nonsignificant after adjusting for each of the
above variables with the exception of disease phase, in which
case the hazard of relapse among patients with chro n i c
GVHD was 0.2 times the hazard among patients without
GVHD (95% CI 0.05-0.1; P = .03).
D i s e a s e - F ree Survival 
DFS experience is summarized in Table 2. Twelve of
59 patients survived without disease a median of 1208 days
(3.3 years) after second BMT (range, 374-3318 days). The
Kaplan-Meier estimate of DFS among all patients 2 years
after second BMT was 23% (Figure 1). DFS varied consider-
ably between disease groups, as shown in Figure 2, and age
g roups, as shown in Figure 3. Ten of the 24 AML patients
w e re disease-free versus only 2 of 13 patients with ALL. Of
the 18 patients transplanted for lymphoma, there were no
d i s e a s e - f ree survivors. None of the patients with CML or
multiple myeloma survived without disease. Age had a major
e ffect on DFS, as patients ≤17 years had an estimated 2-year
DFS of 59%, compared with 9% in patients >17 years. In
addition, patients transplanted in remission had a superior
DFS compared with those transplanted in relapse (2-year
DFS estimates of 50% versus 12%, respectively). 
To assess the potential association of various individual
clinical factors with the hazard of failure from death or re l a p s e ,
univariate Cox re g ression models were fitted for the end point
of DFS. Age >17 years, a diagnosis other than AML, relapse at
second transplantation, and the use of a chemotherapy-only
p reparative regimen for the second transplantation each
a p p e a red to be associated with an increased hazard of failure .
Summarized in Table 4 are the results of the univariate re g re s-
sion models for each of these factors. The hazard of failure
among patients >17 years was 4.7 times higher than that
among patients ≤17 (95% CI 2.1-10.7; P < .001). Incre a s i n g
age was also associated with failure when age was considere d
as a continuous variable (P = .006). Failure was signific a n t l y
higher among patients transplanted in relapse compared with
patients transplanted in remission (HR = 2.6; 95% CI 1.3-5.3;
P = .008). The hazard of failure among patients with diagnoses
other than AML was higher compared with that for patients
with AML. In part i c u l a r, the HR for lymphoma patients re l a-
tive to AML patients was 3.2 (95% CI 1.5-6.6; P = .002),
w h e reas the hazard of failure for patients with ALL was 2.0
times as large as that for AML patients (95% CI 0.9-4.5; P =
.08). The hazard of failure for all patients with diagnoses other
than AML was 2.6-fold higher than that for patients with
AML (95% CI 1.4-4.9; P = .003). Patients who re c e i v e d
chemotherapy-only preparative regimens for their second
transplantation had a higher hazard than patients whose
Table 3. Causes of Death After Second Transplantation
Relapse 14
Nonrelapse mortality
Acute graft-versus-host disease 7
Chronic graft-versus-host disease 4
Infection 6
Veno-occlusive disease 6
Diffuse alveolar damage 4
Other 5
Figure 1. Estimates of the probability of nonrelapse mortality, disease-free survival, and relapse for 59 patients after second transplantation. 
Years After Second Transplantation
276
p reparative regimen contained TBI (HR = 2.8; 95% CI 1.6-
5.0; P < .001). The interval from first to second transplanta-
tion was not associated with DFS. When the fir s t - t o - s e c o n d
BMT interval was dichotomized to ≤1 versus >1 year, the haz-
a rd ratio was 0.70 favoring the longer interval (95% CI 0.4-
1.3). In addition, the type of donor for the second transplanta-
tion was not statistically significantly associated with DFS.
With matched related donors as the re f e rence group, the haz-
a rd ratios for mismatched related and URD were 0.8 (95% CI
0.4-1.7) and 1.1 (95% CI 0.5-2.2), re s p e c t i v e l y.
Among the 4 factors that showed statistically signific a n t
association with hazard of failure, many pairs were moder-
ately to highly correlated with each other, as highlighted in
Table 1. For example, AML patients tended to be younger
and more often had TBI-containing preparative regimens for
the second transplantation. Because of these correlations, it
becomes difficult to determine whether the apparent associa-
tions seen from the univariate analyses are real or due to the
c o rrelation of 1 factor with another, or a combination of the
two. Nested re g ression models were studied to see if the addi-
tion of a particular factor significantly improved the model
that did not contain the additional factor. The results of these
analyses indicated that each of the factors—age, phase of dis-
ease, and use of a TBI-containing re g i m e n — s i g n i f i c a n t l y
i m p roved any re g ression model that did not contain the fac-
t o r. The addition of d i a gnosis to models that already con-
F i g u r e 2. Disease-free survival estimates for acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and lymphoma patients after 
second transplantation.
Figure 3. The effect of age (pediatrics, ≤17 years, versus adults, >17 years) on disease-free survival.
Years After Second Transplantation
Years After Second Transplantation
AML (n = 24)
ALL (n = 13)
Lymphoma (n = 18)
Pediatrics (n = 17)
Adults (n = 42)
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tained TBI, age, or phase of disease did not s i g n i fic a n t l y
i m p rove the appropriate model, however. These results sug-
gest that age, phase of disease, and conditioning regimen each
a re associated with the hazard of failure, even after adjusting
for other factors that show an association through univariate
analysis. The results also suggest, however, that the appare n t
superior outcome of patients transplanted for AML may be
because, on average, AML patients were younger (P < .001)
and more AML patients received TBI-containing condition-
ing regimens (P = .004). In addition, more AML patients were
transplanted in remission, although this diff e rence was not
statistically significant (P = .33). 
F i g u re 4 demonstrates that outcome pro g re s s i v e l y
w o r sens as the number of risk factors increases. For exam-
ple, 4 of 5 patients with no risk factor and 7 of 11 patients
with a single risk factor were disease-free survivors (esti-
mated 2-year DFS 80% and 63%, respectively). On the
c o n t r a ry, only 1 of 12 patients with 2 risk factors surv i v e d
d i s e a s e - f ree (17%), and of the 31 patients with 3 or 4 risk
factors, there were no disease-free survivors.
DISCUSSION
We examined the results of 59 patients who received a
second allogeneic transplantation after relapsing after an
autologous transplantation. The estimated probabilities of
NRM, relapse, and DFS 3 years after the second BMT were
53%, 26%, and 21%, re s p e c t i v e l y. NRM was 41% in the
first 100 days. In general, younger patients, patients trans-
planted in remission, and those receiving a TBI-based re g i-
men had a better chance of DFS after second transplanta-
tion. Patients with AML also had better DFS than non-AML
cases, although this apparent diff e rence may have been
because the AML patients, on average, had fewer other
adverse risk factors.
The data presented demonstrate that second allogeneic
transplantations, especially in adults, were associated with
significant toxicity and mortality. The NRM of 53% in all
patients re p o rted here is not obviously diff e rent from the
64% rate we have re p o rted in patients receiving two allo-
geneic transplantations [22-29]. The toxicity in adults
reported here is very high, with a NRM of 72%. These data
suggest that toxicity carry-over from an initial autologous
transplantation is indeed substantial and likely greater than
that of conventional consolidative chemotherapy. Moreover,
the similarity of NRM between autologous + allogeneic
transplantations and allogeneic + allogeneic transplantations
suggests that much of the toxicity of the second transplanta-
tion is due to the initial transplantation preparative regimen,
not necessarily the effect of GVHD and exposure to
immunosuppressive drugs during the first transplantation.
This study cannot compare the pros and cons of offer-
ing an initial autologous versus allogeneic transplantation.
The data do suggest, however, that children ≤17 years of age
may do well following the second transplantation. However,
it must be emphasized that the survival results reported here
are biased and inflated. Selection bias may favor patients in
better condition and with more stable disease, because to get
Ta b le 4. Univariate Cox Regression Models for Failure Due to Death or Relapse
Hazard ratio*
(95% Confidence Interval)
Age >17 years 4.7 (2.1-10.7)
Diagnosis not acute myelogenous leukemia 2.6 (1.4-4.9)
Relapse at second transplantation 2.6 (1.3-5.3)
Chemotherapy regimen 2.8 (1.6-5.0)
Time between transplantations >1 year 0.7 (0.4-1.3) 
Unrelated donor (versus matched related) 0.8 (0.4-1.7)
Mismatched donor (versus matched related) 1.1 (0.5-2.2)
*Hazard ratio for patients having the risk factor divided by patients without
the risk factor.
F i g u r e 4. Disease-free survival estimates, according to the number of poor risk factors, including age >17 years, transplantation in relapse, chemotherapy
preparative regimen, and diagnosis other than AML.
Years After Second Transplantation
No Risk Factors (n = 5)
Two Risk Factors (n = 12)
Three Risk Factors (n = 18)
Four Risk Factors (n = 13)
One Risk Factor (n = 11)
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to second transplantation patients had to survive for a pro-
longed period of time after their relapse, especially those
patients who needed to secure an unrelated donor. For
example, in a study by Mortimer et al. [4] of 95 AML and
ALL patients who relapsed after an allogeneic transplanta-
tion, only 18 received a second transplant. Supportive care
of transplantation patients has improved considerably, how-
e v e r, so the high NRM noted in those patients, some of
whom received their second transplant more than a decade
ago, may not entirely apply to the current experience.
The results presented here are similar to those re p o rt e d
p reviously [30-33]. In a large study of 169 lymphoma
patients who relapsed after an autologous transplantation,
Vose et al. [30] described 4 patients who went on to re c e i v e
an allogeneic transplant, and 1 survived. Of note in that
study is the dire overall outcome of patients who re l a p s e d
after an autologous transplantation: only 11% were DFS at
12 months postrelapse. Chiang et al. [31] described 7 AML
patients who received second allogeneic transplants after
autologous transp l a nt failure; all 7 died. Ts a i et al. [ 3 2 ]
re p o rted only 2 of 14 lymphoma and 1 of 6 AML patients
s u rviving after a second transplantation. Of note, the NRM
in that re p o rt was very high, with 17 of 20 patients dying of
NRM. Last, the sole optimistic study was re p o rted by de
Lima et al. [33], in which 8 NHL patients received a second
allogeneic transplant, and 4 survived disease-free. In that
series, all survivors were transplanted in remission, and
indeed, of the 6 patients in which remission status was
assessed, 5 of 6 were in clinical remission before the second
transplantation. This is quite diff e rent from our experience,
w h e re only 3 of 18 patients were transplanted in re m i s s i o n ,
and may reflect on the importance of achieving re m i s s i o n
b e f o re attempting a second transplantation.
In conclusion, the data suggest that allogeneic trans-
plantations should not be routinely planned as a salvage
strategy after autologous transplantation, especially in
adults. The strategy may be acceptable for childre n ,
although considerations of selection bias may make this
strategy appear better than it actually is. For adults, if an
allogeneic approach is considered after a failed autologous
transplantation, thought should be given to experimental
approaches such as protocols exploring the use of nonmye-
loablative, low-dose preparative regimens (minitransplanta-
tions) [33-36]. The power of an allogeneic immune GVL
e ffect was demonstrated in these second transplantation
patients by the low hazard ratio of relapse in the patients
who developed GVHD. Given the high morbidity and mor-
tality associated with a traditional allogeneic second trans-
plantation, harnessing a GVL effect while reducing re g i-
m e n - related toxicity, as in nonmyeloablative appro a c h e s ,
would seem an especially attractive therapeutic choice. 
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